- Home
- IMCR vs NAT Comparison
IMCR vs NAT Comparison
Compare IMCR & NAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCR | NAT |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United Kingdom | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2016 | 1997 |
Fundamental Metrics
Financial Performance| Metric | IMCR | NAT |
|---|---|---|
| Price | $30.88 | $5.85 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 10 | 2 |
| Target Price | ★ $66.33 | $4.00 |
| AVG Volume (30 Days) | 556.7K | ★ 4.9M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | N/A | ★ 8.50% |
| EPS Growth | ★ 30.39 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $249,428,000.00 | N/A |
| Revenue This Year | $14.57 | $77.72 |
| Revenue Next Year | $8.21 | N/A |
| P/E Ratio | ★ $122.16 | $525.49 |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $27.56 | $2.60 |
| 52 Week High | $40.71 | $6.70 |
Technical Indicators
Market Signals| Indicator | IMCR | NAT |
|---|---|---|
| Relative Strength Index (RSI) | 61.86 | 52.56 |
| Support Level | $27.66 | $5.07 |
| Resistance Level | $31.56 | $6.30 |
| Average True Range (ATR) | 1.12 | 0.32 |
| MACD | 0.28 | 0.09 |
| Stochastic Oscillator | 73.84 | 45.45 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.